AI English summary of an SEC filing — figures as filed
IDEXX Laboratories IDXXIDEXX Laboratories said cash used by financing activities in 2024 was $878.1 million, compared to $442.0 million in 2023, with the increase driven by repurchases of common stock of $837.0 million in 2023 compared to $71.9 million in the prior year. The amount includes a 1% excise tax paid on certain stock repurchases.
Key points
AI summaryIDEXX Laboratories said cash used by financing activities in 2024 was $878.1 million, compared to $442.0 million in 2023, with the increase driven by repurchases of common stock of $837.0 million in 2023 compared to $71.9 million in the prior year. The amount includes a 1% excise tax paid on certain stock repurchases.
The company said operating cash flow in 2024 increased $22.5 million compared to 2023, with the increase in net income and noncash adjustments reflecting a $61.5 million charge related to an ongoing litigation matter.
As of December 31, 2024, IDEXX Laboratories had cash and cash equivalents of $288.3 million, compared to $453.9 million as of the end of 2023, and had outstanding borrowings of $250.0 million under its $1.25 billion Credit Facility, with remaining borrowing availability of $998.1 million.
The company currently anticipates approximately $1.5 billion of share repurchases in 2025, subject to market conditions. It also anticipates paying off its 2025 Series C Notes of €88.9 million when due in June 2025 and its 2025 Series B Notes of $75.0 million when due in December 2025.
Key figures
Fiscal year ended December 31, 2024
- Revenue
- $3.9B
- Operating income
- $1.1B
- Net income
- $888M
- EPS
- $10.67
- Gross profit
- $2.4B
- Operating cash flow
- $929M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Increase in Cash Used for Share Repurchases
IDEXX Laboratories said cash used by financing activities in 2024 was $878.1 million, compared to $442.0 million in 2023, with the increase driven by repurchases of common stock of $837.0 million in 2023 compared to $71.9 million in the prior year. The amount includes a 1% excise tax paid on certain stock repurchases.
Source · Based on the MD&A text of the filing
Operating Cash Flow Increase and Litigation-Related Costs
The company said operating cash flow in 2024 increased $22.5 million compared to 2023, with the increase in net income and noncash adjustments reflecting a $61.5 million charge related to an ongoing litigation matter.
Source · Based on the MD&A text of the filing
Cash Balance and Available Borrowing Capacity
As of December 31, 2024, IDEXX Laboratories had cash and cash equivalents of $288.3 million, compared to $453.9 million as of the end of 2023, and had outstanding borrowings of $250.0 million under its $1.25 billion Credit Facility, with remaining borrowing availability of $998.1 million.
Source · Based on the MD&A text of the filing
2025 Share Repurchase Plans and Senior Note Maturities
The company currently anticipates approximately $1.5 billion of share repurchases in 2025, subject to market conditions. It also anticipates paying off its 2025 Series C Notes of €88.9 million when due in June 2025 and its 2025 Series B Notes of $75.0 million when due in December 2025.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…